愛污传媒

Skip to main content

Oxford University researchers start trial for HIV vaccine

Share
TORONTO -

Researchers at the University of Oxford in England are trialling a potential breakthrough vaccine for HIV that they hope could also serve as a cure for infected individuals.

The clinical trial, , will test the HIVconsvX vaccine. University of Oxford professor Tomas Hanke says the vaccine is a "mosaic," capable of targeting a range of HIV-1 variants

He told CTV's Your Morning on Tuesday that if successful, the trial could open up the possibility that this single vaccine could be used across the globe.

"Most of the field has been focusing on protection through the use of broadly neutralizing antibodies. Our vaccine aims to use killer T cells," Hanke said.

While most HIV vaccine candidates work by generating antibodies from B cells, Hanke explained that HIVconsvX uses the immune responses from T cells, a type of white blood cell that can kill virus-infected or cancerous cells, to target the most vulnerable regions of HIV.

"When [the] virus gets into the body, it infects cells, and they start to produce more of the viruses and spread the infection, and our killer T cells are going to kill these virus factories in the bodies before it can hopefully establish a generalized infection," Hanke said.

Alternatively, Hanke said the vaccine could slow the virus down and help the broadly neutralizing antibodies generated by B cells, together with the killer T cells, to stop the infection.

According to the university, the trial will assess the HIVconsvX vaccine's safety, tolerability, and immunogenicity.

The trial involves 13 healthy, HIV-negative adults aged 18 to 65 in the U.K. who are not considered to be at a high risk of infection. The participants will receive one dose of the vaccine and will get a booster shot at four weeks.

Not only are researchers at Oxford testing if the vaccine can prevent infection in HIV negative individuals, but the "complex program" also aims to evaluate whether the drug could be used in HIV positive individuals as a cure.

Hanke said future trials will also look at combining the vaccine with other, antiviral drugs in an attempt to "establish control of the virus in the body."

, 37.6 million people globally were living with HIV in 2020. Of these, 35.9 million were adults and 1.7 million were children under 15 years old.

While an effective HIV vaccine has been elusive for 40 years, Hanke acknowledged that certain treatments have made the quality of life better for those suffering from HIV.

"It's not a death sentence anymore; [medications] have changed this disease into a chronic infection," he said.

However, Hanke noted that there are downsides to these treatments.

"Antiviral treatment doesn't get rid of the virus, and it has to be used for the rest of the life and this magnifies all the medical side effects that these drugs may have," Hanke said.

Hanke said there is a social stigma that comes with those who use these treatments, and there are issues of adherence and affordability with taking a daily medication, especially for those with HIV in poorer countries.

"Even in the context of using these antiviral drugs as prevention, vaccine is still the best and most economical solution and likely a key component of any strategy to end the epidemic," Hanke said.

Oxford researchers anticipate results from the trial, which is part of the European Aids Vaccine Initiative, will be reported by April 2022.

CTVNews.ca Top Stories

Canadian musician Jacob Hoggard has been found not guilty of sexually assaulting a young woman in northeastern Ontario eight years ago. The former Hedley frontman had pleaded not guilty to sexual assault.

Police have arrested a Toronto woman in connection with three recent homicides and investigators say that they believe two of the victims may have been 'randomly targeted.'

The body of a British Columbia mountain climber has been located and recovered after the 39-year-old man was reported missing during a solo climb on Washington state's Mount Baker earlier this week.

A teen charged with the murder of another teen on Prince Edward Island last year has pleaded guilty to a lesser charge of manslaughter.

A Saskatchewan man living in the United States has pleaded guilty to possessing child pornography after he unknowingly provided disturbing videos to an FBI agent he thought was a pedophile.

Local Spotlight

Chantal Kreviazuk is set to return to Winnipeg to mark a major milestone in her illustrious musical career.

From the beaches of Cannes to the bustling streets of New York City, a new film by a trio of Manitoba directors has toured the international film festival circuit to much pomp and circumstance.

A husband and wife have been on the road trip of a lifetime and have decided to stop in Saskatchewan for the winter.

The grave of a previously unknown Canadian soldier has been identified as a man from Hayfield, Man. who fought in the First World War.

A group of classic car enthusiasts donated hundreds of blankets to nursing homes in Nova Scotia.

Moving into the second week of October, the eastern half of Canada can expect some brisker fall air to break down from the north

What does New Westminster's t蓹m蓹sew虛tx史 Aquatic and Community Centre have in common with a historic 68,000-seat stadium in Beijing, an NFL stadium and the aquatics venue for the Paris Olympics? They've all been named among the world's most beautiful sports venues for 2024.

The last living member of the legendary Vancouver Asahi baseball team, Kaye Kaminishi, died on Saturday, Sept. 28, surrounded by family. He was 102 years old.

New data from Greater Vancouver and the Fraser Valley shows a surge in supply and drop in demand in the region's historically hot real estate market.